Acrux Limited
Research Acrux Limited (ACR.AX) with Bullrun company financials, valuation charts, model signals, and historical stock context.
Key Metrics
- TickerACR.AX
- ExchangeAU
- CountryAustralia
- SectorHealthcare
- IndustryBiotechnology
- CurrencyAUD
- Financial periodFY2026
- RevenueAUD 4.30M
- Revenue growth261.2%
- Net income-AUD 604.00K
- Free cash flowAUD 1.02M
- Gross margin100.0%
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2026 | AUD 4.30M | -AUD 604.00K | AUD 1.02M | 100.0% | 0 | AUD 1.71M | AUD 2.52M | AUD 1.47M |
| FY2025 | AUD 1.19M | -AUD 5.95M | -AUD 5.48M | 100.0% | -0.02 | AUD 863.00K | AUD 3.64M | AUD 1.02M |
| FY2024 | AUD 5.09M | -AUD 5.80M | -AUD 4.58M | 22.3% | -0.02 | AUD 2.95M | AUD 3.70M | AUD 3.28M |
| FY2023 | AUD 8.43M | -AUD 764.00K | AUD 584.00K | 93.4% | 0 | AUD 6.23M | AUD 2.35M | AUD 8.70M |
| FY2022 | AUD 1.72M | -AUD 9.83M | -AUD 9.28M | 100.0% | -0.03 | AUD 5.83M | AUD 2.08M | AUD 9.09M |
About Acrux Limited
Acrux Limited, together with its subsidiaries, develops and commercializes topically applied pharmaceutical products in Australia, the United States, Europe, and internationally. The company offers Dapsone 7.5% and 5% gels for the treatment of acne vulgaris; Nitroglycerine 0.4% ointments for the treatment of moderate to severe pain associated with chronic anal fissure; Lidocaine and Prilocaine creams USP 2.5% for local analgesia and pre-treatment for infiltration anesthesia;
Related stock research
Other Healthcare stocks
Frequently asked questions
What does Acrux Limited do?
Acrux Limited, together with its subsidiaries, develops and commercializes topically applied pharmaceutical products in Australia, the United States, Europe, and internationally.